BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16739368)

  • 21. [Proton pump inhibitors according to need. Always for heartburn].
    Labenz J
    MMW Fortschr Med; 2002 Jun; 144(23):34-7. PubMed ID: 12119901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
    Richter JE; Kahrilas PJ; Sontag SJ; Kovacs TO; Huang B; Pencyla JL
    Am J Gastroenterol; 2001 Nov; 96(11):3089-98. PubMed ID: 11721754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
    Bigard MA; Genestin E
    Aliment Pharmacol Ther; 2005 Oct; 22(7):635-43. PubMed ID: 16181303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
    Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
    Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
    Johnsson F; Moum B; Vilien M; Grove O; Simren M; Thoring M
    Scand J Gastroenterol; 2002 Jun; 37(6):642-7. PubMed ID: 12126240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Adachi K; Hashimoto T; Hamamoto N; Hirakawa K; Niigaki M; Miyake T; Taniura H; Ono M; Kaji T; Suetsugu H; Yagi J; Komazawa Y; Mihara T; Katsube T; Fujishiro H; Shizuku T; Hattori S; Yamamoto S; Kinoshita Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1392-8. PubMed ID: 14675268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
    Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
    Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A; Dattilo M
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
    Hatlebakk JG; Berstad A; Carling L; Svedberg LE; Unge P; Ekström P; Halvorsen L; Stallemo A; Hovdenak N; Trondstad R
    Scand J Gastroenterol; 1993 Mar; 28(3):224-8. PubMed ID: 8446846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
    Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM
    Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
    Howden CW; Henning JM; Huang B; Lukasik N; Freston JW
    Am J Gastroenterol; 2001 Jun; 96(6):1704-10. PubMed ID: 11419818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
    Li MJ; Li Q; Sun M; Liu LQ
    Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
    Freston JW
    Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.